Functional Brands, Inc. Common Stock
MEHA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$179.22K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $179,221.00 |
|---|---|
| Enterprise Value | $-51,743,779.00 |
| Earnings per Share | $0.08 |
| Beta | 0.2 |
| Outstanding Shares | 42,671,660 |
Return
| Return on Equity | -34.10% |
|---|---|
| Return on Assets | -31.35% |
| Return on Invested Capital | -35.52% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 13.32 |
| Enterprise Value to EBIT | -1.32 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 1.00% |
|---|---|
| Total Invested | $203▼ 99.72% |
| Investors Holding | 1▼ 11.00% |
About Evommune, Inc.
45 employees
CEO: Luis C. Pena
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic sponta...